Entrada Therapeutics Inc Cash Flow-to-Debt Ratio
Entrada Therapeutics Inc cash flow-to-debt ratio. Entrada Therapeutics Inc (TRDA) has a Cash Flow-to-Debt Ratio of -0.50x as of June 2026, meaning its operating cash flow of $-32.46 Million could theoretically repay 0% of its total liabilities ($65.47 Million) in one year. Check Entrada Therapeutics Inc earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Entrada Therapeutics Inc (2019–2025)
Cash flow-to-debt ratio of Entrada Therapeutics Inc from 2019 to 2025. Historical debt coverage capacity for Entrada Therapeutics Inc across 7 annual periods. Check Entrada Therapeutics Inc total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Entrada Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2019–2025)
Entrada Therapeutics Inc cash flow-to-debt ratio by year from 2019 to 2025. Year-by-year debt coverage analysis for Entrada Therapeutics Inc. For the full cash flow conversion analysis, see Entrada Therapeutics Inc operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.80x | $-128.51 Million | $71.25 Million | ▼ -323.8% |
| 2024 | -0.43x | $-41.56 Million | $97.64 Million | ▼ -169.1% |
| 2023 | 0.62x | $139.80 Million | $226.83 Million | ▲ +126.0% |
| 2022 | -2.37x | $-93.79 Million | $39.50 Million | ▲ +66.8% |
| 2021 | -7.15x | $-50.86 Million | $7.12 Million | ▼ -2276.8% |
| 2020 | -0.30x | $-25.57 Million | $85.02 Million | ▲ +6.0% |
| 2019 | -0.32x | $-10.80 Million | $33.76 Million | — |